- Home
- ETNB vs JMIA Comparison
ETNB vs JMIA Comparison
Compare ETNB & JMIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- JMIA
- Stock Information
- Founded
- ETNB 2018
- JMIA 2012
- Country
- ETNB United States
- JMIA Germany
- Employees
- ETNB N/A
- JMIA N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- JMIA Catalog/Specialty Distribution
- Sector
- ETNB Health Care
- JMIA Consumer Discretionary
- Exchange
- ETNB Nasdaq
- JMIA Nasdaq
- Market Cap
- ETNB 867.4M
- JMIA 793.3M
- IPO Year
- ETNB 2019
- JMIA 2019
- Fundamental
- Price
- ETNB $8.21
- JMIA $4.91
- Analyst Decision
- ETNB Strong Buy
- JMIA Buy
- Analyst Count
- ETNB 8
- JMIA 2
- Target Price
- ETNB $30.14
- JMIA $7.30
- AVG Volume (30 Days)
- ETNB 671.4K
- JMIA 2.6M
- Earning Date
- ETNB 11-06-2024
- JMIA 11-13-2024
- Dividend Yield
- ETNB N/A
- JMIA N/A
- EPS Growth
- ETNB N/A
- JMIA N/A
- EPS
- ETNB N/A
- JMIA N/A
- Revenue
- ETNB N/A
- JMIA $186,488,000.00
- Revenue This Year
- ETNB N/A
- JMIA $3.80
- Revenue Next Year
- ETNB $133.30
- JMIA $5.50
- P/E Ratio
- ETNB N/A
- JMIA N/A
- Revenue Growth
- ETNB N/A
- JMIA 1.54
- 52 Week Low
- ETNB $6.58
- JMIA $2.24
- 52 Week High
- ETNB $16.63
- JMIA $15.04
- Technical
- Relative Strength Index (RSI)
- ETNB 56.59
- JMIA 43.44
- Support Level
- ETNB $7.10
- JMIA $4.99
- Resistance Level
- ETNB $8.19
- JMIA $5.58
- Average True Range (ATR)
- ETNB 0.37
- JMIA 0.36
- MACD
- ETNB 0.15
- JMIA -0.01
- Stochastic Oscillator
- ETNB 70.76
- JMIA 8.02
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.